Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950075 · ClinicalTrials.gov registry record · Phase 2
Study of INBRX-109 in Conventional Chondrosarcoma
A Phase 2 study of Conventional Chondrosarcoma, sponsored by Inhibrx Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04950075 is a Phase 2 study of Conventional Chondrosarcoma that is active but no longer recruiting, run by Inhibrx Biosciences. The registered enrollment target is 206 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04950075, a Phase 2 study of Conventional Chondrosarcoma, is active but no longer recruiting, sponsored by Inhibrx Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INBRX-109
Study Locations (20)
California
- Precision NextGen Oncology & Research Center - Beverly Hills
- University of California, San Francisco (UCSF) - San Francisco
- Sarcoma Oncology Center - Santa Monica
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center - Chicago
- Rush Cancer Center - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Arizona
- Mayo Clinic Cancer Center - Phoenix
Colorado
- University of Colorado - Denver
Connecticut
- Yale Cancer Center - New Haven
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04950075
The ClinicalTrials.gov registry entry for NCT04950075 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inhibrx Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Conventional Chondrosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04950075 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04950075 about?
NCT04950075 is a clinical study titled "Study of INBRX-109 in Conventional Chondrosarcoma". Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
What is the current status of trial NCT04950075?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2021-09-23. Estimated completion is 2026-12.
What conditions does trial NCT04950075 study?
This clinical trial studies the following conditions: Conventional Chondrosarcoma.
What interventions are being tested in trial NCT04950075?
The interventions under investigation include: Placebo (DRUG), INBRX-109 (DRUG).
Who is sponsoring clinical trial NCT04950075?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04950075 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.